These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 23014527

  • 1. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
    Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M.
    Clin Cancer Res; 2012 Nov 15; 18(22):6169-77. PubMed ID: 23014527
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
    Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M.
    Clin Cancer Res; 2008 Sep 15; 14(18):5731-4. PubMed ID: 18794081
    [Abstract] [Full Text] [Related]

  • 6. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ.
    Cancer; 2013 Jan 15; 119(2):356-62. PubMed ID: 22810899
    [Abstract] [Full Text] [Related]

  • 7. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
    Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG, Riely GJ.
    Cancer; 2012 Dec 01; 118(23):5840-7. PubMed ID: 22605530
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
    Fakhruddin N, Mahfouz R, Farhat F, Tfayli A, Abdelkhalik R, Jabbour M, Yehia L, Mahfoud Z, Zaatari G.
    Oncol Rep; 2014 Nov 01; 32(5):2223-9. PubMed ID: 25120214
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J, Chen JQ, Zhang L, Liang ZY.
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct 01; 41(10):652-6. PubMed ID: 23302304
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG.
    Int J Clin Exp Pathol; 2013 Oct 01; 6(9):1880-9. PubMed ID: 24040454
    [Abstract] [Full Text] [Related]

  • 16. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.
    Lung Cancer; 2014 May 01; 84(2):196-202. PubMed ID: 24629638
    [Abstract] [Full Text] [Related]

  • 17. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, Klikovits T, Hoda MA, Grusch M, Berger W, Klepetko W, Hegedus B, Dome B.
    Eur J Cancer; 2014 Jul 01; 50(10):1819-1828. PubMed ID: 24768329
    [Abstract] [Full Text] [Related]

  • 18. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.
    J Thorac Oncol; 2012 Dec 01; 7(12):1815-1822. PubMed ID: 23154553
    [Abstract] [Full Text] [Related]

  • 19. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
    Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL.
    Mod Pathol; 2013 Oct 01; 26(10):1307-19. PubMed ID: 23619604
    [Abstract] [Full Text] [Related]

  • 20. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.
    Bircan S, Baloglu H, Kucukodaci Z, Bircan A.
    Med Oncol; 2014 Aug 01; 31(8):87. PubMed ID: 24973952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.